Welcome to the MAPS Newsroom, where you will find resources, connections to experts, and education about all things psychedelic: research, harm reduction, policy, history, and more. 

To request an interview or appearance, complete the media request form and a member of our communications team will be in touch if we are able to grant an interview. 

  • Media requests are reviewed in the morning and evening every Monday-Friday (except holidays)
  • If you are on a deadline of less than 24 hours or over the weekend, please complete the form and call 831-429-6362 ext 303 to leave a message alerting us to your deadline. 

Get started with resources to support your research with the latest news from MAPS, the MAPS Bulletin, or below. 

If you are planning to report on trauma, we recommend reading these two articles about how to do so conscientiously: Meaningful Consent in Trauma Journalism and How Not To Write About Rape by writer & editor Jina Moore. 

Our Experts

MAPS ORG and MAPS PBC experts are knowledgeable resources on many topics related to psychedelic research, policy, culture, and news. If one of our experts isn’t available, we may be able to connect you with another expert in the field — just be sure to check that box on the media request form

Rick Doblin, Ph.D.
Founder & Executive
Rick in the news
Amy Emerson
Chief Executive Officer 
Amy in the news
Betty Aldworth
Director of Communications
Betty in the news
Berra Yazar-Klosinski, Ph.D. 
Deputy Director 
Berra in the news 
Ismail Lourido Ali, J.D. 
Policy & Advocacy Counsel
Ismail in the news
Merete Christiansen
Associate Director of
Merete in the news
Corine de Boer, M.D., Ph.D.
Chief Medical Officer
Corine in the news
Sara Gael, M.A.
Harm Reduction Officer
Sara in the news
Shannon Carlin, M.A., A.M.F.T
Director and Head of Training and Supervision
Shannon in the news
Liana Gillooly 
Development Officer 
Liana in the news
Rebecca Matthews
Chief Clinical Operations Officer 
Rebecca in the news
Natalie Ginsberg, M.S.W.
Director of Policy &
Natalie in the news
Michael Mithoefer, M.D.
Senior Medical Director for Medical Affairs 
Michael in the news


Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. We aim to transcend geopolitical and social boundaries and intentionally cultivate interactions with thought leaders from a wide range of interest areas that demonstrate the broad applications of the healing potential of psychedelics. We proactively build trust and common ground with everyone we meet. MAPS’ EIN is 59-2751953. Visit to learn more.


Founded in 2014, MAPS Public Benefit Corporation (MAPS PBC) is a wholly-owned subsidiary of MAPS. MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. MAPS and MAPS PBC employ more than 100 people with about three quarters of them at MAPS PBC and one quarter at MAPS. Visit to learn more.



Psychedelic Compounds


MDMA was invented in 1912 by chemist Anton Köllisch of Merck but was largely unexplored for medical or psychiatric use until 1976, when Alexander Shulgin and Leo Zeff identified its potential in therapy. Due to its popularity in the party scene, in 1983 MDMA was caught up in the War on Drugs and swiftly prohibited, halting all research into its potential as an adjunct, or catalyst, to therapy. In 2001, Rick Doblin, Ph.D., outlined MAPS’ strategy for the development of MDMA-assisted therapy for PTSD and in 2004, the first study participant was treated by Dr. Michael Mithoefer and Annie Mithoefer in Charleston, South Carolina. 

Today, MAPS is sponsoring the second of two Phase 3 trials for FDA evaluation of MDMA-assisted therapy for PTSD, anticipated to conclude with approval in 2023. MDMA-assisted therapy may hold potential in the treatment of eating disorders, anxiety associated with advanced-stage illness, and social anxiety. Research into treatment for couples in which one partner has been diagnosed with PTSD combines MDMA-assisted therapy with conjoint cognitive behavioral therapy. Learn more about our progress on our MDMA research page

MDMA is not the same as “Ecstasy” or “molly.” Substances sold in unregulated markets under these names may contain MDMA, but frequently also contain unknown and/or dangerous adulterants. In laboratory studies, pure MDMA has been proven sufficiently safe for human consumption when taken a limited number of times in moderate doses. 

MDMA Digital Media & Resources


MDMA Videos from MAPS

MAPS’MDMA Research

MAPS & MDMA in the News

MDMA in the MAPS Bulletin

MDMA Stats

Generic name: midomafetamine

Chemical name: 3,4-Methylenedioxymethamphetamine

Compound type: Synthetic

Discovered: 1912

Prohibited: 1985

Anticipated FDA approval: 2023

Mechanism of action: induces release of serotonin and oxytocin; attenuates fear, increases empathy

Expected reactions in therapeutic setting: transient increase in blood pressure and heart rate, muscle tightness, decreased appetite, nausea, sweating, feeling cold, pupil dilation, and restlessness


Updated May 2021

Therapists trained in the MAPS protocol: ~900

People treated in MAPS-sponsored MDMA studies: ~350

People with symptom improvement: 88%

People with loss of PTSD diagnosis: 67%

Long-term prognosis: Continued reduction of symptoms

Years to cost-savings: <Four

Quality-of-life-years returned: >Five


MAPS’ Marijuana News 

Marijuana Videos from MAPS

MAPS’ Marijuana Research

MAPS & Marijuana in the News

Marijuana in the MAPS Bulletin



LSD Videos from MAPS

MAPS’ LSD Research

MAPS & LSD in the News

LSD in the MAPS Bulletin


MAPS’ Ibogaine News

Ibogaine Videos from MAPS

MAPS’ Ibogaine Research

MAPS & Ibogaine in the News

Ibogaine in the MAPS Bulletin


MAPS’ Ayahuasca News

Ayahuasca Videos from MAPS

MAPS’ Ayahuasca Research

MAPS & Ayahuasca in the News

Ayahuasca in the MAPS Bulletin


Psilocybin Research

Psilocybin Videos from MAPS

Psilocybin in the MAPS Bulletin


Ketamine Research

Ketamine Videos from MAPS

Ketamine in the MAPS Bulletin


DMT Research

DMT Videos from MAPS

DMT in the MAPS Bulletin


Mescaline Research

Mescaline Videos from MAPS

Mescaline in the MAPS Bulletin